Clinical trial · Interventional
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
A Phase 1 Study for Safety and Tolerability of BMS-986205 Administered in Combination With Nivolumab (BMS-936558) in Advanced Malignant Tumors
NCT03192943CI-TRIAL-00037882completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986205 | Drug | — | UNRESOLVED |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dose Escalation
- description
- monotherapy and combination therapy
- interventionNames
- Drug: BMS-986205
- Biological: Nivolumab
Primary outcomes (5)
- measure
- Incidence of Adverse Events (AEs)
- timeFrame
- 15 months
- description
- Safety and Tolerability
- measure
- Incidence of Serious Adverse Events (SAEs)
- timeFrame
- 15 months
- description
- Safety and Tolerability
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com * Participants must have histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) * Participants must have received, and then progressed or been intolerant to standard treatment regimen in the advanced or metastatic setting * Eastern Cooperative Oncology Group performance status of ≤ 1 Exclusion Criteria: * Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease are excluded * History of congenital or autoimmune hemolytic disorders * History or presence of hypersensitivity or idiosyncratic reaction to methylene blue Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.